A comparison of metabolic effects of doxazosin versus bendrofluazide in hypertensive British Asians

Background People from British South Asian communities have an increased risk of mortality from coronary heart disease (CH D). Doxazosin, a selective alpha(1)-adrenergic blocker, in addition to lowering blood pressure, has been shown to have positive effects on glucose metabolism and lipid profiles in patients with hypertension. Aim We studied doxazosin (1-8 mg) and bendrofluazide (2.5 mg) in patients of British South Asian origin with existing mild to moderate hypertension (doxazosin n = 78; bendrofluazide n = 82), to compare their effects on glucose and lipid metabolism in this group. Design of study A 34-week randomised, double-blind, parallel-group, multicentre study. Setting Primary care in the UK. Method All doxazosin patients started with an initial dose of 1 mg once daily, titrated to a maximum 8 mg once daily if diastolic blood pressure was >90 mmHg or was not